Morepen Lab Share Price Target 2027,2030,2035,2040

Share of Morepen Laboratories Ltd is currently trading at around Rs.132/- Investors are asking for the Morepen Lab Share Price Target 2027, 2030, 2035 and 2040. In this article, we will discuss about the business prospects and financial performance of the Company and based on our discussion and analysis will tell you the Morepen Lab Share Price Target 2027, 2030, 2035 and 2040.

Discussion & Analysis of Business & Financial performance with future business prospects of Morepen Laboratories Ltd:

Morepen Laboratories Ltd is an Indian pharmaceutical and healthcare company engaged in manufacturing active pharmaceutical ingredients (APIs), generic formulations, and home healthcare and medical diagnostic devices. The company has established a presence in domestic and international markets, supported by its manufacturing facilities, regulatory credentials and export network. Its products include pharmaceutical ingredients used in medicines for cardiovascular diseases, diabetes and other chronic conditions, along with glucometers, blood pressure monitors and other diagnostic products.

Morepen’s business momentum strengthened significantly in the first quarter of FY 2026-27. According to its reported results for the quarter ended June 2026, revenue reached approximately ₹575.31 crore, registering year-on-year growth of 34%. EBITDA increased by 207% to ₹87.72 crore, while net profit rose by 394% to ₹56.35 crore. Export revenue also recorded strong growth, reflecting improved international demand and business performance.

The pharmaceutical API business remains a key revenue contributor. Morepen is working to strengthen its position in regulated international markets through manufacturing quality, new product development and long-term customer relationships. Its medical devices business provides additional diversification, benefiting from rising awareness of home-based healthcare, diabetes management and preventive diagnostics.

A major development is the company’s ₹825 crore long-term contract manufacturing and development organisation (CDMO) mandate from a global multinational pharmaceutical company. Commercial supplies under this programme have commenced, creating an opportunity for more predictable revenues and deeper relationships with global pharmaceutical customers. Morepen also increased its API and CDMO reactor capacity from 535 kilolitres to 614 kilolitres during 2026.

Future Business Prospects

Morepen Laboratories’ future growth prospects appear encouraging, supported by three major drivers: expansion of its CDMO business, growth in pharmaceutical exports and increasing demand for medical devices. The company’s ₹825 crore CDMO programme could provide a stronger revenue base as commercial supplies scale up. Its plans to increase manufacturing capacity further, potentially reaching 1,200 kilolitres by FY30, could help it accommodate additional contracts and improve production efficiency.

Another growth opportunity is the development of higher-value pharmaceutical products. In September 2026, Morepen announced its first US Abbreviated New Drug Application (ANDA) submission for generic Sitagliptin tablets. If regulatory requirements are met and the product achieves commercial acceptance, this could support its move into finished formulations and broaden its international business. However, regulatory approval and market adoption are not guaranteed.

The medical devices segment could also benefit from India’s growing diabetes patient population, increased home monitoring and demand for affordable diagnostic equipment. Expansion into connected healthcare and continuous glucose monitoring may offer additional opportunities over the longer term.

Nevertheless, investors should monitor risks, including raw material price fluctuations, competition in generic medicines, regulatory compliance, capital expenditure requirements and the company’s ability to convert announced opportunities into sustainable cash flows. Rapid profit growth in a single quarter should not automatically be assumed to continue at the same pace.

Overall, Morepen Laboratories appears to be entering an important growth phase, transitioning from a traditional API manufacturer towards a broader pharmaceutical manufacturing, CDMO and healthcare devices business. Sustained execution, successful capacity utilisation and healthy operating margins will be crucial to its long-term performance. These prospects are encouraging, but investors should also assess valuation, debt, cash flows and subsequent quarterly results before making investment decisions.

Share Price Targets:

Morepen Lab Share Price Target 2030

Based on the above discussion and analysis, the share price of Morepen Laboratories Ltd may touch the level of around Rs.145-150 in 2027

Morepen Lab Share Price Target 2027

Based on the above discussion and analysis, the share price of Morepen Laboratories Ltd may touch the level of around Rs.275–300 in 2030

Morepen Lab Share Price Target 2035

Based on the above discussion and analysis, the share price of Morepen Laboratories Ltd may touch the level of around Rs.600–650 in 2035

Morepen Lab Share Price Target 2040

Based on the above discussion and analysis, the share price of Morepen Laboratories Ltd may touch the level of around Rs.1300–1400 in 2040

Disclaimer: Investments in Capital Market/Share Prices are subject to market fluctuations and are dependent on several factors. These predictions are based on the current market conditions and the future market expectations. Investors are advised to take into consideration all these factors before making any investment in Capital Market. This article should not be treated as Investment advisory and is for general Guidance & Educational purpose only. We keep revising our share price targets based on the latest information available with us. Please keep visiting our website regularly to keep yourself updated. News4You does not offer investment advice and does not encourage any action based on its content.

Read Also: